103.67
price down icon1.89%   -2.00
after-market Dopo l'orario di chiusura: 104.49 0.82 +0.79%
loading

Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie

pulisher
May 14, 2025

Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis - The Globe and Mail

May 14, 2025
pulisher
May 14, 2025

Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis - The Motley Fool

May 14, 2025
pulisher
May 14, 2025

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Is Axsome Therapeutics Stock Worth The Risk? A Comprehensive Analysis - Barchart.com

May 14, 2025
pulisher
May 14, 2025

Fibromyalgia Treatment Market to Reach $3.88 Billion by 2033 | - openPR.com

May 14, 2025
pulisher
May 14, 2025

Axsome in $570 million loan and revolving credit facility with Blackstone - The Pharma Letter

May 14, 2025
pulisher
May 14, 2025

Frontier Capital Management Co. LLC Has $4.47 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Q2 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat

May 14, 2025
pulisher
May 13, 2025

Transcript : Axsome Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

William Blair Analysts Boost Earnings Estimates for AXSM - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Cubist Systematic Strategies LLC Invests $9.89 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Fairmount Funds Management LLC Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Major Depressive Disorder Market Growth to Accelerate - openPR.com

May 13, 2025
pulisher
May 13, 2025

Axsome Therapeutics enters $570M term loan, credit facility with Blackstone - MSN

May 13, 2025
pulisher
May 13, 2025

Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News

May 13, 2025
pulisher
May 13, 2025

Axsome Therapeutics Enters $570 Million Credit Deal With Blackstone - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Axsome Therapeutics (AXSM) Secures $570 Million Credit Facility - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Axsome Therapeutics Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

3 Monster Stocks in the Making - aol.com

May 13, 2025
pulisher
May 13, 2025

Axsome secures $570 million credit facility from Blackstone - Investing.com

May 13, 2025
pulisher
May 13, 2025

Axsome secures $570 million credit facility from Blackstone By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Axsome Therapeutics Secures $570 Million Financing Facility with Blackstone, Retires Previous Loan - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone - The Manila Times

May 13, 2025
pulisher
May 13, 2025

BNP Paribas Financial Markets Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Northern Trust Corp - MarketBeat

May 13, 2025
pulisher
May 13, 2025

HC Wainwright Issues Negative Outlook for AXSM Earnings - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Price T Rowe Associates Inc. MD Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

May 13, 2025
pulisher
May 12, 2025

William Blair Has Bullish Forecast for AXSM FY2028 Earnings - MarketBeat

May 12, 2025
pulisher
May 12, 2025

Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $180.00 at HC Wainwright - MarketBeat

May 12, 2025
pulisher
May 12, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Schonfeld Strategic Advisors LLC - MarketBeat

May 12, 2025
pulisher
May 11, 2025

Axsome Therapeutics (NASDAQ:AXSM) Given New $162.00 Price Target at Robert W. Baird - MarketBeat

May 11, 2025
pulisher
May 11, 2025

Balyasny Asset Management L.P. Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

May 11, 2025
pulisher
May 11, 2025

Axsome Therapeutics (NASDAQ:AXSM) Trading Up 5.6% Following Better-Than-Expected Earnings - MarketBeat

May 11, 2025
pulisher
May 11, 2025

Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat

May 11, 2025
pulisher
May 10, 2025

Axsome Therapeutics (NASDAQ:AXSM) Releases Quarterly Earnings Results, Beats Estimates By $0.46 EPS - MarketBeat

May 10, 2025
pulisher
May 10, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat

May 10, 2025
pulisher
May 10, 2025

BVF Inc. IL Has $117.44 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

May 10, 2025
pulisher
May 10, 2025

FY2025 EPS Estimates for AXSM Lifted by Cantor Fitzgerald - MarketBeat

May 10, 2025
pulisher
May 09, 2025

Axsome Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Alethea Capital Management LLC Has $62.13 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

May 09, 2025
pulisher
May 08, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 14.2% in April - MarketBeat

May 08, 2025
pulisher
May 08, 2025

Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025 - MSN

May 08, 2025
pulisher
May 08, 2025

Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN

May 07, 2025
$65.61
price down icon 0.15%
$19.08
price down icon 1.19%
$32.29
price down icon 1.61%
$22.75
price down icon 7.56%
$92.08
price down icon 2.56%
biotechnology ONC
$219.95
price down icon 2.13%
Capitalizzazione:     |  Volume (24 ore):